Application of MALDI imaging for the diagnosis of classical Hodgkin lymphoma

Abstract

Hodgkin lymphoma (HL) is a distinctive lymphoma subtype characterized by rareness of tumor cells [Hodgkin's and Reed-Sternberg (HRS) cells in classical HL and lymphocytic and histiocytic cells in lymphocyte predominant HL] as well as the vast majority of the surrounding inflammatory-like cellular infiltrate. Still the onset of this highly variable disease is not completely understood. Proteome analysis can lead to the identification of potential proteins capable of elucidating malignant growth and survival in HL. Especially MALDI imaging could result in pinpointing differentially expressed proteins, which might represent potential marker molecules. In this study, we were able to distinguish between classical Hodgkin lymphoma and lymphadenitis with a sensitivity and specificity of 83.92 and 89.37%, respectively.

New developments in the pathology of malignant lymphoma. A review of the literature published from August 2010–October 2010

“…Schwamborn et al [50] used matrix-assisted laser desorption/ionization (MALDI) imaging and were able to separate HL from reactive lesions with a sensitivity and specificity of 83.92% and 89.37%, respectively.…”

Current frontiers in clinical research application of MALDI imaging mass spectrometry

“…Schwamborn et al for example, conducted the first proteomic study on Hodgkin lymphoma that was performed on human lymph node samples [105].…”

Recent advances in single-cell MALDI mass spectrometry imaging and potential clinical impact

“…A potential advantage of using MS imaging platforms for tissue evaluation is the ability to identify molecular changes associated with the tissue that are not yet detectable from histopathological evaluation. Numerous studies have been performed on cancerous tissues including lung [13,89,90], breast/mammary [91–94], oral [95], pancreatic [96], gastric [97], renal [98], colon [99], prostate [16,100,101], ovarian [102–104], Hodgkin’s lymphoma [105] and brain [88,106,107]. Resolving molecular information from cancerous tissue to the single-cell level will allow building of reference systems with more specific signatures of disease and healthy states.…”